“When patients get an infection from a CVC they have a 50% chance of dying ... it’s a terrible price for a patient to pay.”

— William Hunter, MD, president/CEO of Angiotech explaining why the central vascular catheter (CVC) was the right product to try anti-infective compound 5-FU on first, “Angiotech to file for 510(k) of anti-infective CVC product,” pp. 1,9.